A dry powder delivery device may be configured to provide micronized dry powder particles to airways of a user. The device may include a cylindrical container delimiting a chamber containing at least one magnetically-responsive object, a motor external to said chamber, a magnet external to the chamber and rotatably coupled with the motor, and an outflow member configured to direct airflow to a user. The magnetically-responsive object may be coated with micronized dry powder particles, and the motor may be operable to rotate the magnet about an axis. Rotation of the magnet creates a magnetic field that causes the magnetically-responsive object to move in response to the magnetic field and collide with a side wall of the container to deaggregate the dry powder particles and aerosolize the dry powder in the chamber.

A holding device including a sleeve wall having an outer wall surface and an inner wall surface. The inner wall surface forms a capsule insertion channel extending through an entirety of the sleeve wall. A lip is at an end of the capsule insertion channel and extends toward a center of the capsule insertion channel. The inner wall surface has a recess at a first distance along the inner wall surface from the lip, a base extending outward from the outer wall surface of the sleeve wall; and a flexible retaining element in the recess. The recess being configured to prevent movement of the flexible retaining element along the inner wall. The flexible retaining element having a cross-sectional profile with a first width at a side closer to the lip, and a second width at a side farther from the lip, the first width being larger than the second width.

Methods and devices are provided for delivering one or more substances within at least one body cavity. Such devices include at least one nosepiece having at least one capsule including a volume V.sub.sub of the substances; at least one base in communication with the nosepiece, the base having at least one chamber configured to confine pressurized fluid at volume V.sub.PF and pressure P.sub.PF, and at least one hollow puncturing member having at least one sharp end and a second end in fluid communication with the base. The first and second ends are fluidly interconnected by at least one hollow tube. A fluid inlet port of the capsule is configured in terms of size and shape to interface in a sealable manner with at least one end of the at least one puncturing member.

A dry powder inhaler (1) has a chamber (12) for housing a capsule and an inhalation channel (22), the chamber (12) is shaped in order to determine an agitated motion of the capsule in the chamber (12) during an inhalation of a user, the inhaler (1) comprises a capsule-piercing mechanism (30) arranged to pierce a capsule in the chamber (12) and a monitoring system (40) comprising an accelerometer (42) arranged on a printed circuit board (48) in order to measure mechanical oscillations determined at least by the agitated motion and by a flow of air through the chamber (12) and/or inhalation channel (22); a detection unit (44) arranged to detect an activation of the capsule-piercing mechanism (30); and an electronic processing unit (46) configured to receive signals from the detection unit (44) and from the accelerometer (42). Reception of a signal from the detection unit (44) triggers processing of signals from the accelerometer (42) by the electronic processing unit (46) in order to generate inhalation data.

An inhaler article includes a tubular housing defining a holder body extending along a longitudinal axis from a mouthpiece end to a consumable receiving end. The holder body includes an inner tube extending along the longitudinal axis and within the tubular housing from a tube intake end to a tube exhaust end. The tube intake end is proximate the consumable receiving end. The inner tube defines an air flow lumen with two or more air flow apertures extending through a wall of the inner tube. An air blocking feature is positioned in the air flow lumen and between two of the air flow apertures. A vibration inducing element disposed on the inner tube proximate to the tube exhaust end or the tube intake end, the vibration inducing element comprises an aperture through the wall of the inner tube and having a tapered or angled downstream aperture edge.

A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided.

Systems and methods of delivering a drug product by inhalation can include a prodrug composition.

A device for delivering a compound to the olfactory region of the nasal cavity includes an actuator body and a tip that removably couples to the actuator body. The actuator body includes a propellant channel in fluid communication with a propellant canister. The tip includes an exit channel, an inlet interface, one or more grooves, and an outlet orifice. The exit channel extends between a proximal end and a distal end of the tip. The inlet interface is positioned about a distal end of the exit channel, and the inlet interface couples to a compound container containing the compound. The grooves are positioned about the inlet interface and direct propellant from the propellant channel into the compound container, thereby agitating and entraining the compound in the compound container with the released propellant. The compound and the propellant then travel through the exit channel and out the outlet orifice.

An inhaler (400) for electronically supervised parenteral administration of a dry powder pharmaceutical composition comprising: storage means (410) for the pharmaceutical composition in a form of a dry powder; administration means (411) for ad- ministration of the pharmaceutical composition; memory (404) and processing means (402); communication means (401); controlled blocking means (403) for blocking administration of the pharmaceutical composition, wherein the inhaler (400) is adapted to receive data corresponding to an administration scheme (11), to determine whether a mobile device (300) with an authorisation token assigned thereto is present, and to control the controlled blocking means (403) so as to allow administration of the pharmaceutical composition only with compliance with the administration scheme (11) in the presence of the mobile device (300) with the authorisation token (12) assigned thereto.

A capsule for an aerosol-generating device includes a housing. The housing includes an inner frame defining an opening. The housing defines at least one air inlet and at least one air outlet. The capsule also includes an aerosol-forming substrate at least partially within the opening, and a heater supported by the inner frame and extending across at least a portion of the opening. The at least one air inlet, the opening, and the at least one air outlet collectively form at least one airflow pathway through the capsule. The airflow pathway is longer than a thickness of the capsule.